Novartis AG has won approval for its drug Femara to be used in a wider range of British women with breast cancer, the Swiss company said on Thursday.

Britain's Medicines and Healthcare Products Regulatory Agency cleared the medicine for treatment after surgery of postmenopausal women who have hormone-positive early invasive breast cancer. (Scotsman.com)

September 1, 2005

Tumors in cancer-ridden mice shrank by 90 percent after treatment with the drug, researchers report in a study to be released Tuesday. The compound, called OGT2378, appears to block the ability of cancer cells to grow by manipulating the host's immune system. (excite.com)

Posted by news editor | Filed under: Cancer Drugs

June 17, 2005

Promising results from the UK's first clinical trial of a prototype cancer drug have raised the prospect of an effective new treatment against a range of cancers, including breast, prostate, bowel, kidney, ovarian and skin cancer. (Medical News Today)

Posted by news editor | Filed under: Cancer Drugs

May 17, 2005

Pfizer Inc.'s experimental drug Sutent improved survival and reduced tumor growth in patients with a type of stomach cancer, according to a pivotal-stage trial the company unveiled this weekend. (UPMC Cancer Centers)

Posted by news editor | Filed under: Stomach Cancer

May 16, 2005

No one could have been more surprised than the doctors themselves. They were just hoping to relieve the symptoms of a deadly blood disorder and ended up treating the disease itself. (Washington Post)

Posted by news editor | Filed under: Cancer Drugs

April 22, 2005

A drug commonly used to treat Type 2 diabetes may prevent cancer, researchers have said. (BBC)

Posted by news editor | Filed under: Cancer Drugs

April 21, 2005

A new drug stops the growth of certain ovarian cancer cells and their ability to metastasize, report Philadelphia scientists. (Monsters and Critics)

Posted by news editor | Filed under: Ovarian Cancer

April 18, 2005

The drug, Sphingomab, may even completely wipe out some tumors -- all while leaving healthy tissue alone, early laboratory and animal studies show. (WebMD)

Posted by news editor | Filed under: Cancer Drugs

April 11, 2005

Celgene Corp. on Monday said initial results from two pivotal-stage trials show that its blood cancer drug Revlimid in combination with chemotherapy significantly delays progression of multiple myeloma in relapsed patients. (Reuters)

Posted by news editor | Filed under: Multiple Myeloma

March 25, 2005

Pfizer has agreed to pay $50 million to Coley Pharmaceutical Group with the potential for up to $455 million in additional milestone payments, plus royalties, in an exclusive global license agreement to develop, manufacture and commercialize Coley's anti-cancer drug ProMune (CPG 7909). (Daily News Central)

Posted by news editor | Filed under: Cancer Drugs

December 8, 2004

The data shows that in postmenopausal women with hormone sensitive, early breast cancer, Arimidex reduces the risk of breast cancer returning by an additional 26 per cent over and above the 50 per cent reduction in risk already offered by Tamoxifen, and it has fewer side effects.

Posted by news editor | Filed under: Cancer Drugs

August 22, 2004

A new treatment for asbestos-related lung cancer has been registered for use in New Zealand.

Alimta (Pemetrexed) has been shown to extend the life expectancy of patients with malignant pleural mesothelioma an average of 12 months, compared with six to eight months on existing treatments. (New Zealand Herald)

Posted by news editor | Filed under: Mesothelioma